EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing

Shi-Yong Fu iD, Xiu-Zhen Chen, Peng-Cheng Yi, Jie Gao, Wei-Xiao Wang, Shuang-Lin Gu, Jing-Han Gao, Du-Xian Liu, Han-Feng Xu, Yi Zeng, Chun-Mei Hu iD, Qin Zheng iD und 1 weitere

Antimicrobial Agents and Chemotherapy · 02.04.2025 · 69 (4)

DOI: 10.1128/aac.01683-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.04.2025. Verfasst von Shi-Yong Fu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Enterobacter cloacae, Bacteremia, Phage Therapy, Carbapenems. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Nanjing Municipal Health Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The increase in multidrug-resistant (MDR) Enterobacter cloacae complex (ECC) infections, particularly those resistant to carbapenems, underscores the urgent need for alternative therapies. Phage therapy, with its specific bactericidal action, offers a promising solution. However, there remains a shortage of well-characterized ECC-targeting phages, and dosing and timing optimization for ECC-specific phage cocktails is largely unexplored. In this study, we isolated and characterized three novel lytic phages with diverse genome sizes and host ranges. Notably, ФEBU8 demonstrated broad-spectrum activity, lysing both Enterobacter species and Acinetobacter baumannii . ФECL22 displayed stability across a wide temperature range (4–50°C), pH tolerance (6–10), and a burst size of 19 PFU/cell, with OmpA identified as its receptor. Our formulated phage cocktail, comprising ФEBU8, ФECL22, and ФECL30, effectively rescued mice with E. cloacae bacteremia in a dose-dependent manner, with a mid-dose regimen showing particularly strong efficacy. Immediate phage administration achieved full survival, whereas a combined prophylactic and therapeutic regimen (“−24 + 6”) also resulted in 100% survival. These findings highlight the critical roles of dosing and timing in optimizing phage therapy for carbapenem-resistant Enterobacter infections, with prophylactic use providing a valuable window for delayed treatment and a promising strategy for combating severe bacterial infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enterobacter cloacaeBacteremiaPhage TherapyCarbapenemsEnterobacteriaceae InfectionsBacteriophagesCarbapenem-Resistant EnterobacteriaceaeAnimalsMiceAnti-Bacterial AgentsMicrobial Sensitivity TestsAcinetobacter baumanniiDrug Resistance, Multiple, BacterialFemale

Stichwörter der Autor:innen

Enterobacter cloacae complexOmpAdose optimizationhost rangephage therapyprophylactic usereceptor

Substanzen

CarbapenemsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Oncology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Tuberculosis, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
  • Clinical Research Center, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Pathology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
  • The Clinical Infectious Disease Center of Nanjing, Nanjing, China.

ORCID-Profile: Shi-Yong Fu, Chun-Mei Hu, Qin Zheng, Wei Chen

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • Nanjing Municipal Health Bureau

Zitieren

APA

Fu, S. Y., Chen, X. Z., Yi, P. C., Gao, J., Wang, W. X., Gu, S. L., Gao, J. H., Liu, D. X., Xu, H. F., Zeng, Y., Hu, C. M., Zheng, Q., & Chen, W. (2025). Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing. Antimicrobial Agents and Chemotherapy, 69(4). https://doi.org/10.1128/aac.01683-24

Vancouver

Fu SY, Chen XZ, Yi PC, Gao J, Wang WX, Gu SL, et al. Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing. Antimicrobial Agents and Chemotherapy. 2025;69(4). doi:10.1128/aac.01683-24

BibTeX
@article{Fu2025,
  author = {Fu, Shi-Yong and Chen, Xiu-Zhen and Yi, Peng-Cheng and Gao, Jie and Wang, Wei-Xiao and Gu, Shuang-Lin and Gao, Jing-Han and Liu, Du-Xian and Xu, Han-Feng and Zeng, Yi and Hu, Chun-Mei and Zheng, Qin and Chen, Wei},
  title = {Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {4},
  doi = {10.1128/aac.01683-24}
}
Kostenlos starten →